EKTA.B

54.45

+0.37%↑

EKTA.B

54.45

+0.37%↑

EKTA.B

54.45

+0.37%↑

EKTA.B

54.45

+0.37%↑

EKTA.B

54.45

+0.37%↑

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Slēgts

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.9M -9.1M
EPS	-0.015
Darbinieki	4
EBITDA	-1.8M -8.9M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	38M 90M
Iepriekšējā atvēršanas cena	0
Iepriekšējā slēgšanas cena	0

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. apr. 23:33 UTC

Karstas akcijas

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026. g. 28. apr. 23:24 UTC

Peļņas

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026. g. 28. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026. g. 28. apr. 22:46 UTC

Peļņas

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026. g. 28. apr. 22:37 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026. g. 28. apr. 22:15 UTC

Peļņas

Galvenie ziņu notikumi

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026. g. 28. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026. g. 28. apr. 23:31 UTC

Peļņas

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026. g. 28. apr. 23:31 UTC

Peļņas

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026. g. 28. apr. 23:30 UTC

Peļņas

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026. g. 28. apr. 23:30 UTC

Peļņas

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026. g. 28. apr. 23:19 UTC

Tirgus saruna

Peļņas

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026. g. 28. apr. 23:09 UTC

Peļņas

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026. g. 28. apr. 23:03 UTC

Tirgus saruna

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026. g. 28. apr. 22:51 UTC

Peļņas

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026. g. 28. apr. 22:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 28. apr. 22:48 UTC

Tirgus saruna

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026. g. 28. apr. 22:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026. g. 28. apr. 22:32 UTC

Peļņas

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026. g. 28. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026. g. 28. apr. 22:22 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026. g. 28. apr. 22:17 UTC

Tirgus saruna

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026. g. 28. apr. 22:14 UTC

Peļņas

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026. g. 28. apr. 22:14 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026. g. 28. apr. 22:07 UTC

Tirgus saruna

Galvenie ziņu notikumi

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Citi krājumi no sektora

EKTA.B

Elekta AB

54.45

↑ +0.37%

Vivesto AB

Pārskats

Akcijas cenas izmaiņa

Galvenie mērījumi

Dividendes

Tirgus statistika

Vivesto AB Grafiks

Saistītās ziņas

Salīdzinājums

Vivesto AB Prognoze

Finanšu rādītāji

Par Vivesto AB

Citi krājumi no sektora